Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy.

Trial Profile

Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2011

At a glance

  • Drugs Nicotine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2011 Trial phase changed from II to I/II as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Results presented at the 15th International Congress of Parkinson's Disease and Movement Disorders.
    • 03 Dec 2010 Results have been reported in a Neuraltus Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top